ERYTECH Announces the availability of the exemption document relating to the proposed combination with Pherecydes Post author:Cleo Sciscioli Post published:May 23, 2023 Post category:Newsroom You Might Also Like ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia August 29, 2016 ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference May 30, 2018 REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 June 24, 2022
ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia August 29, 2016
